Citius Pharmaceuticals (NASDAQ:CTXR – Get Free Report) is one of 894 public companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Citius Pharmaceuticals to similar businesses based on the strength of its earnings, dividends, profitability, risk, analyst recommendations, valuation and institutional ownership.
Earnings and Valuation
This table compares Citius Pharmaceuticals and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Citius Pharmaceuticals | $7.11 million | -$37.43 million | -0.31 |
| Citius Pharmaceuticals Competitors | $17.41 billion | $3.19 billion | 555.14 |
Citius Pharmaceuticals’ peers have higher revenue and earnings than Citius Pharmaceuticals. Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
Analyst Recommendations
This is a summary of recent ratings and price targets for Citius Pharmaceuticals and its peers, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Citius Pharmaceuticals | 1 | 1 | 3 | 0 | 2.40 |
| Citius Pharmaceuticals Competitors | 7850 | 13806 | 25845 | 1039 | 2.41 |
Citius Pharmaceuticals currently has a consensus target price of $6.00, indicating a potential upside of 1,074.86%. As a group, “Pharmaceuticals” companies have a potential upside of 28.14%. Given Citius Pharmaceuticals’ higher possible upside, research analysts plainly believe Citius Pharmaceuticals is more favorable than its peers.
Risk and Volatility
Citius Pharmaceuticals has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Citius Pharmaceuticals’ peers have a beta of -0.05, indicating that their average share price is 105% less volatile than the S&P 500.
Profitability
This table compares Citius Pharmaceuticals and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Citius Pharmaceuticals | N/A | -59.57% | -34.47% |
| Citius Pharmaceuticals Competitors | -2,391.71% | -206.09% | -14.88% |
Summary
Citius Pharmaceuticals peers beat Citius Pharmaceuticals on 8 of the 13 factors compared.
Citius Pharmaceuticals Company Profile
Citius Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for serious medical conditions. Its work has included products and drug candidates in oncology and critical care, with an emphasis on addressing unmet treatment needs. Its oncology business is associated with LYMPHIR (denileukin diftitox-cxdl), an FDA-approved treatment for adults with relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy. Citius has also developed Mino-Lok, an investigational antibiotic lock solution intended to treat catheter-related bloodstream infections.
Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
